Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men
Authors
Keywords
-
Journal
Oncology and Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-07
DOI
10.1007/s40487-022-00184-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MEK inhibitors for the treatment of non-small cell lung cancer
- (2021) Jing Han et al. Journal of Hematology & Oncology
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Announcing the Lancet Commission on Prostate Cancer
- (2021) Nick James et al. LANCET
- Genomic Profiling of Prostate Cancers from Men with African and European Ancestry
- (2020) Yusuke Koga et al. CLINICAL CANCER RESEARCH
- PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer
- (2020) Wendan Yu et al. Cell Death & Disease
- The Impact of African Ancestry on Prostate Cancer Disparities in the Era of Precision Medicine
- (2020) Deyana D. Lewis et al. Genes
- The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
- (2019) Yan Li et al. Frontiers in Pharmacology
- Treatment of Advanced Prostate Cancer
- (2019) Min Yuen Teo et al. Annual Review of Medicine
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities
- (2018) Shyh-Han Tan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma
- (2018) Veerendra Koppolu et al. Journal of Cancer Research and Therapeutics
- Safety of combining radiotherapy with immune-checkpoint inhibition
- (2018) William L. Hwang et al. Nature Reviews Clinical Oncology
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
- (2017) Xinxin Zhu et al. Oncotarget
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer
- (2016) Kazuhiko Shien et al. LUNG CANCER
- PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
- (2016) Heidrun Gevensleben et al. Oncotarget
- The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
- (2015) H. Gevensleben et al. CLINICAL CANCER RESEARCH
- High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
- (2015) Yueh-Min Lin et al. PLoS One
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
- (2014) Suzanne Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
- (2011) H Payne et al. BRITISH JOURNAL OF CANCER
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started